[Special Stock] BC World Pharm Rises on News of Producing Allergy Treatment Drugs Amid Pfizer Vaccine Allergy Restrictions

[Asia Economy Reporter Minwoo Lee] BC World Pharm's stock price is on the rise. The British government announced that people who have experienced severe allergic reactions to drugs or food will be restricted from receiving Pfizer's COVID-19 vaccine, highlighting the news that BC World Pharm produces medication that treats such allergies.

As of 10:41 AM on the 10th, BC World Pharm's stock price recorded 23,550 KRW, up 9.03% from the previous day. Jun Ray, head of the UK's Medicines and Healthcare products Regulatory Agency (MHRA), stated on the 10th (local time), "People with a history of anaphylaxis to vaccines, medicines, or food should not receive the Pfizer-BioNTech vaccine," which appears to have acted as positive news for the production of anaphylaxis treatment drugs.

Anaphylaxis refers to a severe systemic reaction characterized by acute respiratory distress, decreased blood pressure, loss of consciousness, and shock symptoms caused by antigen-antibody immune responses after ingesting certain foods or drugs. In the UK, which was the first country to start administering the COVID-19 vaccine jointly developed by Pfizer and BioNTech, cases showing such allergic reactions were reported on the same day, prompting relevant authorities to establish these guidelines.

Meanwhile, BC World Pharm produces Cuphrin Injection, which contains epinephrine as its main ingredient. Cuphrin Injection is used as an auxiliary treatment for anaphylactic shock and cardiac arrest.

This content was produced with the assistance of AI translation services.